Hormone Optimization for Weight Loss: Why HRT and GLP-1 Work Better Together

Medically reviewed by Dr. Susana Querido, MD, triple board-certified in Family Medicine, Aesthetic Medicine, and Anti-Aging & Regenerative Medicine.

Every week, patients arrive at medically supervised weight loss consultations carrying the same frustration: they’ve tried caloric restriction, increased exercise, and in some cases already started a GLP-1 medication, yet the scale barely moves. For many of them, the explanation isn’t a lack of effort. It’s a hormonal problem that hasn’t been diagnosed yet. Hormone optimization for weight loss sits at the center of Dr. Querido’s clinical approach at Greenwich MD, and it’s a distinction that separates genuinely thorough care from the one-note programs that focus only on the medication and nothing else.

Metabolism isn’t a single dial that gets turned up or down by willpower alone. It’s a system of interconnected signals, and when one signal is off, the rest compensate in ways that make fat storage more likely, muscle loss faster, and appetite harder to regulate. Understanding which hormones are involved, and how they interact with newer weight loss medications, is the first step toward a plan that actually holds.

Which Hormones Actually Drive Weight Gain

Roughly 40% of patients Dr. Querido evaluates for medically supervised weight loss have at least one undiagnosed hormonal imbalance that directly undermines their ability to lose weight. Four systems most often drive that pattern.

Thyroid Hormones

The thyroid regulates basal metabolic rate. Even a mild underperformance (subclinical hypothyroidism) can slow calorie burning by several hundred calories per day without producing textbook symptoms like fatigue or hair loss.

The catch: most standard checkups only measure TSH, which can appear normal even when free T3 and free T4 are subtly low. A patient can be told their thyroid is “fine” and still be running metabolically cold.

Testosterone (Men and Women)

• In men: decline accelerates after 35. Low levels correlate with visceral fat gain, muscle loss, and slower resting metabolism.
• In women: perimenopause dips are normal but often unaddressed. Same muscle-loss pattern.
• Why it compounds: muscle tissue burns more calories at rest than fat. Losing it quietly over years creates a compounding metabolic disadvantage.

Estrogen and Progesterone

Declining estrogen during perimenopause and menopause redirects fat storage from hips and thighs toward the abdomen. That is not just cosmetic. It is a metabolic shift associated with increased insulin resistance.

One study published in the Journal of Clinical Endocrinology & Metabolism found that women gaining weight during the menopause transition showed insulin sensitivity reductions of up to 15% independent of body weight changes alone.

Insulin and Cortisol

• Insulin resistance: cells stop responding efficiently to insulin. Blood sugar stays elevated longer, fat breakdown is suppressed, and cravings for carbohydrate-rich foods intensify.
• Chronically elevated cortisol: promotes abdominal fat storage and drives late-night appetite. Patients under sustained stress often find standard diet programs fail them not because of behavioral weakness but because their cortisol is keeping the fat-storage switch flipped on.

Why GLP-1 Medications Plateau Without Hormone Support

GLP-1 receptor agonists like semaglutide and tirzepatide have genuinely changed the conversation around obesity medicine. In clinical trials they produced average weight loss of 15% to 22% of body weight over 68 weeks. But trial populations don’t always reflect the patients who walk into a clinic after years of failed attempts, carrying unresolved metabolic issues that were never part of the study criteria.

The Mechanism Behind the Plateau

When a patient with undiagnosed subclinical hypothyroidism starts a GLP-1 medication, they typically see initial progress followed by an early plateau around weeks 8 to 12. The medication is doing its job on the appetite side, but the thyroid-driven metabolic slowdown limits how much that reduced intake translates into actual fat loss.

From the outside, it looks like the medication stopped working. From the inside, the patient feels like they’ve failed again.

“A GLP-1 medication is not a complete weight loss strategy. If the hormonal foundation is unstable, the medication is fighting an uphill battle, and the patient feels it as a plateau that willpower cannot break through.” — Dr. Querido

Muscle Loss: The Second Hidden Cost

GLP-1 medications reduce total caloric intake. Without adequate testosterone levels and resistance exercise, a significant portion of the weight lost can come from lean muscle rather than fat.

• Losing muscle during a GLP-1 course lowers resting metabolic rate.
• Lower metabolic rate makes weight regain more likely after tapering off.
• Optimizing testosterone and protein metabolism before or alongside therapy protects against that outcome.

For patients curious about how the two main GLP-1 options compare, Dr. Querido’s detailed breakdown of tirzepatide vs semaglutide explains the clinical differences and helps clarify which medication may be better suited to a given metabolic profile.

The Bloodwork That Changes the Conversation

Standard primary care labs aren’t built for metabolic optimization. They’re built to rule out disease. A TSH within the broad “normal” reference range doesn’t mean the thyroid is functioning optimally for that individual patient. It means it isn’t flagged for treatment.

The Full Panel at Greenwich MD

Every weight loss intake includes a comprehensive hormone panel:

• Thyroid: full panel (TSH, free T3, free T4, reverse T3), not just TSH.
• Insulin: fasting insulin targeting the optimal 2 to 6 range, not just the broad “normal” range that ends around 25.
• Testosterone: total and free, in both men and women.
• Estrogen and progesterone: cycle-appropriate for pre-menopausal women, baseline for post-menopausal.
• Cortisol: often a 4-point salivary cycle to catch inverted rhythms.

A Real Case: Missed by Telehealth, Caught by the Panel

One patient Dr. Querido saw earlier this year had been on semaglutide for four months through a telehealth service and had lost only six pounds. Her labs, which the telehealth provider had never ordered, revealed free T3 in the bottom quartile of the reference range alongside a fasting insulin of 19.

After initiating low-dose thyroid support and adjusting her nutrition protocol to target insulin sensitivity, she lost an additional 14 pounds over the following 10 weeks, on the same semaglutide dose she’d already been taking.

When HRT and GLP-1 Therapy Work Together

The pairing of testosterone replacement therapy and GLP-1 therapy is a logical response to how these systems interact.

The Combined Effect

• Testosterone supports lean muscle synthesis and maintenance.
• GLP-1 medications reduce caloric intake and improve insulin signaling.
• Together: the body preferentially burns fat rather than muscle. Faster onset, better muscle preservation, lower rates of weight regain after tapering.

Estrogen and Progesterone for Perimenopause and Menopause

For women going through perimenopause or menopause, estrogen and progesterone optimization add another dimension. Restoring estrogen to physiological levels can:

• Reduce central fat redistribution.
• Improve sleep quality, which is independently tied to weight regulation through ghrelin and leptin.
• Lower the cortisol load that often accompanies hormonal transition.

These aren’t side benefits. For many menopausal women trying to lose weight, they’re the preconditions that make any weight loss strategy viable.

A Real Case: 54, Post-Menopausal, 18 lbs in 12 Weeks

A 54-year-old postmenopausal woman came to Dr. Querido’s practice after gaining 22 pounds over 18 months despite no significant change in diet or activity. Her labs showed estrogen in the postmenopausal range, testosterone below the female reference range, and a cortisol rhythm that was inverted (low in the morning, elevated at night).

Dr. Querido initiated bioidentical hormone therapy and a targeted cortisol-support protocol before adding tirzepatide three weeks later. The patient lost 18 pounds in the first 12 weeks of combined therapy, after losing almost nothing in the 18 months prior.

Patients interested in what this hormonal support looks like clinically can review Greenwich MD’s full hormonal replacement therapy page. For a broader view of anti-aging and regenerative approaches that complement weight optimization, the NAD+ therapy page offers relevant context on cellular energy support.

Why Most Med Spas and Telehealth Platforms Miss This

The rapid growth of GLP-1 prescribing through telehealth platforms and med spas has made these medications more accessible than ever. That’s largely a positive development given how undertreated obesity has historically been. But accessibility without clinical depth creates a predictable gap.

Where the Gap Comes From

• Telehealth platforms: standardized intake forms and basic safety labs. Not equipped to order or interpret a full thyroid panel alongside fasting insulin, testosterone, and cortisol.
• Med spas: aesthetics businesses first. Excellent at injection technique and skin protocols, but endocrine evaluation isn’t their core competency.
• The result: patients get the prescription. Nothing else.

What a medically managed medical weight loss program can offer instead: a physician who reads the full picture and adjusts the plan accordingly. When a plateau occurs, there is a clinical process to investigate and correct it rather than simply refill the prescription.

This integrated approach is only possible when the same physician manages both hormonal and weight loss protocols, which is precisely what Dr. Querido’s triple board-certification in Family Medicine, Aesthetic Medicine, and Anti-Aging & Regenerative Medicine enables.

Why Greenwich MD

Dr. Querido built her practice around the idea that weight, hormones, and aging aren’t separate clinical categories. They’re expressions of the same underlying biology, and they respond best to treatment that recognizes that connection.

What Sets This Practice Apart

• Triple board-certification in Family Medicine, Aesthetic Medicine, and Anti-Aging & Regenerative Medicine.
• Thorough bloodwork first, individualized protocol second, ongoing monitoring to refine the plan as results develop.
• Both protocols under one roof. HRT and GLP-1 therapy managed by the same physician, in the same practice, so no fragmented care.
• Aesthetic follow-through. Patients who lose significant weight often develop skin laxity or body contour concerns. Body contouring services are available within the same practice, no referrals needed.

If the weight has been resistant, if prior programs have stalled, or if something just feels hormonally off even when labs come back “normal,” this is the kind of evaluation that has been missing.

What Does Hormone Optimization for Weight Loss Cost?

Cost varies because the protocol is individualized. What each patient needs depends on which hormones are out of range, whether GLP-1 medication is prescribed, and whether insurance covers any part of the plan.

What Drives the Cost

• Comprehensive bloodwork: broader panel than a typical checkup because it captures thyroid, insulin, sex hormones, and cortisol. Coverage varies by insurer.
• Physician-led consultation and follow-ups: initial evaluation with Dr. Querido plus two to three follow-ups in the first quarter.
• HRT medications: varies by which hormones are needed and the delivery method (creams, injections, pellets).
• GLP-1 medication: brand-name semaglutide or tirzepatide is the largest recurring cost. Some patients qualify for insurance coverage or manufacturer savings programs. Compounded alternatives are available at lower cost points.
• Ongoing monitoring: quarterly labs to confirm hormone levels stabilize and adjust dosing.

Why the Comprehensive Approach Often Costs Less Long-Term

Patients often frame the choice as “cheap online telehealth vs expensive in-person program.” The real comparison is different. A telehealth prescription that produces a 6-pound loss over 4 months (like the case above) costs less per month but delivers a fraction of the result. When labs are done properly and the plan actually works, the cost per pound lost is often lower with the comprehensive approach.

An exact quote for your specific situation is provided during your consultation, once Dr. Querido reviews your history and identifies which components you actually need.

Risks, Side Effects, and Who Should Avoid This Protocol

Combined hormone optimization and GLP-1 therapy is well tolerated by most candidates. But it is not right for everyone, and the individual components carry real risks that patients should understand before starting.

GLP-1 Medication Side Effects

• Common (first 4 to 8 weeks): nausea, mild GI upset, constipation, fatigue. Usually resolve as the dose titrates up gradually.
• Less common: gallbladder issues (risk rises with rapid weight loss) and pancreatitis (rare, but requires immediate evaluation if severe abdominal pain occurs).
• Boxed warning: thyroid C-cell tumors observed in rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

HRT Considerations by Hormone

• Estrogen: small increase in clot risk, particularly with oral forms in women who smoke or have inherited clotting disorders. Transdermal delivery generally has a lower risk profile.
• Testosterone (men): requires baseline PSA and cardiovascular assessment. Ongoing monitoring for hematocrit changes.
• Testosterone (women): low dose only. Rare cases of acne or unwanted hair growth resolve with dose adjustment.
• Thyroid support: over-correction can cause palpitations, insomnia, or anxiety. Dose is titrated slowly and rechecked at 6 to 8 weeks.

Who Should Not Start This Protocol

• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome (contraindicates GLP-1).
• Active or recent cancer, particularly hormone-sensitive.
• Pregnancy, breastfeeding, or active attempts to conceive.
• History of pancreatitis.
• Uncontrolled cardiovascular disease.
• Severe untreated eating disorder.

Dr. Querido’s evaluation includes a full medical history review before any prescription is written. If the protocol isn’t safe for you, you will be told that directly, and often referred to a different clinical path that is.

See also our clinic overview of peptide therapy at Greenwich MD in Stamford — another physician-supervised protocol for patients who want lab-driven, individualized optimization.

Weight is one of several menopausal changes patients notice. For skin laxity, collagen loss, and mood symptoms that often come with it, see our menopause aesthetic medicine plan.

Frequently Asked Questions